Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV001507973 | SCV001713840 | uncertain significance | not provided | 2020-12-29 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001865930 | SCV002230317 | uncertain significance | PHGDH deficiency | 2021-09-24 | criteria provided, single submitter | clinical testing | This sequence change replaces valine with methionine at codon 72 of the PHGDH protein (p.Val72Met). The valine residue is weakly conserved and there is a small physicochemical difference between valine and methionine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with PHGDH-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Genome- |
RCV003339658 | SCV004049044 | uncertain significance | Neu-Laxova syndrome 1 | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001865930 | SCV004049045 | uncertain significance | PHGDH deficiency | 2023-04-11 | criteria provided, single submitter | clinical testing |